person · Reporting owner

Collard Craig A

Disclosed activity across 4 companies

Tapewire entity: 27346
SEC CIK: 0001363558

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
HERON THERAPEUTICS, INC. /DE/HRTX · Entity 7133	Director · Chief Executive Officer	July 30, 2026	August 03, 2026
TerrAscend Corp.TSNDF · Entity 6184	Director	June 24, 2026	June 25, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

HERON THERAPEUTICS, INC. /DE/

Report date July 30, 2026 · Filed August 03, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	856,492	Ending reported balance After 2026-07-31 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2026-07-30 · Exercise / conversion · Acquired 50,021 · Balance 821,703 F1: Each restricted stock unit represents a contingent right to receive one share of common stock. Row 2 · 2026-07-31 · Exercise / conversion · Acquired 34,789 · Balance 856,492 F1: Each restricted stock unit represents a contingent right to receive one share of common stock.
Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	700,295	Reported balance After 2026-07-30 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-07-30 · Exercise / conversion · Disposed 50,021 · Balance 700,295 F2: On January 30, 2026 (the "Date of Grant"), the Reporting Person was granted 800,337 RSUs which vest upon the following time-based vesting schedule: the RSUs vest in 16 equal quarterly installments beginning one quarter after the Date of Grant. The full amount of the RSUs granted to the Reporting Person is reflected herein.
Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	347,886	Reported balance After 2026-07-31 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2026-07-31 · Exercise / conversion · Disposed 34,789 · Balance 347,886 F3: The restricted stock units vest in 16 equal installments beginning one quarter after the date of grant (January 31, 2025).

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit represents a contingent right to receive one share of common stock.

F2: On January 30, 2026 (the "Date of Grant"), the Reporting Person was granted 800,337 RSUs which vest upon the following time-based vesting schedule: the RSUs vest in 16 equal quarterly installments beginning one quarter after the Date of Grant. The full amount of the RSUs granted to the Reporting Person is reflected herein.

F3: The restricted stock units vest in 16 equal installments beginning one quarter after the date of grant (January 31, 2025).

TerrAscend Corp.

Report date June 24, 2026 · Filed June 25, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Employee Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.44 · Expires 2029-04-24	Direct	0	Reported balance After 2026-06-24 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-24 · Disposition to issuer · Disposed 150,000 · Balance 0 F1: See remarks.
Employee Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.26 · Expires 2029-04-24	Direct	150,000	Reported balance After 2026-06-24 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-06-24 · Grant · Acquired 150,000 · Balance 150,000 F1: See remarks.

Filing footnotes · ownership attribution and instrument terms

F1: See remarks.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

OPIANT PHARMACEUTICALS, INC.

Report date March 02, 2023 · Filed March 03, 2023

Section 16 reporting ended · disclosed 2023-03-03. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Ending reported balance After 2023-03-02 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2023-03-02 · Disposition to issuer · Disposed 53,822 · Balance 2,000 F1: Disposed of pursuant to that certain Agreement and Plan of Merger between the Issuer, Indivior Inc., and Olive Acquisition Subsidiary, Inc., dated as of November 13, 2022 (the "Merger Agreement"), in exchange for a cash payment of $20.00 per share without interest thereon (the "Merger Consideration"). Row 2 · 2023-03-02 · Disposition to issuer · Disposed 2,000 · Balance 0 F2: Disposed of pursuant to the Merger Agreement in exchange for the Merger Consideration. The number of shares disposed of reflects 2,000 shares of Common Stock upon the acceleration of vesting of restricted stock units in accordance with the Merger Agreement.
Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $17.61 · Expires 2028-10-29	Direct	Reported balance After 2023-03-02 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2023-03-02 · Disposition to issuer · Disposed 5,000 · Balance 0 F3: The option was cancelled pursuant to the Merger Agreement, in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of disposed option shares.
Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $8.79 · Expires 2030-06-15	Direct	Reported balance After 2023-03-02 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2023-03-02 · Disposition to issuer · Disposed 2,500 · Balance 0 F3: The option was cancelled pursuant to the Merger Agreement, in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of disposed option shares.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.75 · Expires 2029-06-11	Direct	Reported balance After 2023-03-02 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2023-03-02 · Disposition to issuer · Disposed 2,500 · Balance 0 F3: The option was cancelled pursuant to the Merger Agreement, in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of disposed option shares.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.30 · Expires 2031-06-14	Direct	Reported balance After 2023-03-02 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2023-03-02 · Disposition to issuer · Disposed 2,500 · Balance 0 F3: The option was cancelled pursuant to the Merger Agreement, in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of disposed option shares.

Filing footnotes · ownership attribution and instrument terms

F1: Disposed of pursuant to that certain Agreement and Plan of Merger between the Issuer, Indivior Inc., and Olive Acquisition Subsidiary, Inc., dated as of November 13, 2022 (the "Merger Agreement"), in exchange for a cash payment of $20.00 per share without interest thereon (the "Merger Consideration").

F2: Disposed of pursuant to the Merger Agreement in exchange for the Merger Consideration. The number of shares disposed of reflects 2,000 shares of Common Stock upon the acceleration of vesting of restricted stock units in accordance with the Merger Agreement.

F3: The option was cancelled pursuant to the Merger Agreement, in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of disposed option shares.

Sierra Oncology, Inc.

Report date July 01, 2022 · Filed July 01, 2022

Section 16 reporting ended · disclosed 2022-07-01. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2022-07-01 transaction · row 1 1 source row Row 1 · 2022-07-01 · Disposition to issuer · Disposed 13,500 · Balance 0
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.88 · Expires 2030-05-28	Direct	Reported balance After 2022-07-01 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2022-07-01 · Disposition to issuer · Disposed 10,000 · Balance 0 F2: Pursuant to the terms of the merger agreement between issuer, GlaxoSmithKline plc ("GSK") and a subsidiary of GSK, this option was cancelled on the effective date of the merger in exchange for a cash payment equal to, on a per share basis, the offer price of $55.00 less the exercise price. F1: The option fully vested on May 28, 2021.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.11 · Expires 2031-06-08	Direct	Reported balance After 2022-07-01 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2022-07-01 · Disposition to issuer · Disposed 6,000 · Balance 0 F2: Pursuant to the terms of the merger agreement between issuer, GlaxoSmithKline plc ("GSK") and a subsidiary of GSK, this option was cancelled on the effective date of the merger in exchange for a cash payment equal to, on a per share basis, the offer price of $55.00 less the exercise price. F3: The option fully vested on June 8, 2022.

Filing footnotes · ownership attribution and instrument terms

F1: The option fully vested on May 28, 2021.

F2: Pursuant to the terms of the merger agreement between issuer, GlaxoSmithKline plc ("GSK") and a subsidiary of GSK, this option was cancelled on the effective date of the merger in exchange for a cash payment equal to, on a per share basis, the offer price of $55.00 less the exercise price.

F3: The option fully vested on June 8, 2022.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
April 19, 2024 Filed Apr 19, 2024 20:34 UTC	HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133	Exercise / conversionCommon Stock	13,797	Not disclosed	Not disclosed	Disclosure SEC source: 0000950170-24-046050 · ownership.xml · nonDerivative · entry 1 Collard Craig A · CIK 0001363558 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 262,793 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document
April 03, 2024 Filed Apr 5, 2024 19:57 UTC	HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133	Exercise / conversionRestricted Stock Units · Derivative	62,500	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000950170-24-042226 · ownership.xml · derivative · entry 2 Collard Craig A · CIK 0001363558 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 187,500 Underlying: Common Stock · 62,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning one year after the date of grant, subject to the Reporting Person's continued service to the Issuer through the vesting date. F2 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning one year after the date of grant, subject to the Reporting Person's continued service to the Issuer through the vesting date. Read SEC document
April 03, 2024 Filed Apr 5, 2024 19:57 UTC	HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133	Exercise / conversionCommon Stock	62,500	Not disclosed	Not disclosed	Disclosure SEC source: 0000950170-24-042226 · ownership.xml · nonDerivative · entry 1 Collard Craig A · CIK 0001363558 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 248,996 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document
January 19, 2024 Filed Jan 20, 2024 01:58 UTC	HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133	GrantRestricted Stock Units · Derivative	220,750	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001209191-24-001974 · doc4.xml · derivative · entry 2 Collard Craig A · CIK 0001363558 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 220,750 Underlying: Common Stock · 220,750 shares Expires not disclosed F2 · derivative.exercise_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (01/19/2024). F2 · derivative.expiration_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (01/19/2024). Read SEC document
January 19, 2024 Filed Jan 20, 2024 01:58 UTC	HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133	GrantEmployee Stock Option (Right to Buy) · Derivative	1,324,502	$0.00 Strike: $2.09	$0.00	Disclosure SEC source: 0001209191-24-001974 · doc4.xml · derivative · entry 1 Collard Craig A · CIK 0001363558 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,324,502 Underlying: Common Stock · 1,324,502 shares Expires 2034-01-19 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 48 equal monthly installments beginning one month after the date of grant (01/19/2024). Read SEC document
January 19, 2024 Filed Apr 19, 2024 20:34 UTC	HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133	Exercise / conversionRestricted Stock Units · Derivative	13,797	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000950170-24-046050 · ownership.xml · derivative · entry 2 Collard Craig A · CIK 0001363558 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 206,953 Underlying: Common Stock · 13,797 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (01/19/2024). F2 · derivative.expiration_date: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (01/19/2024). Read SEC document
November 16, 2023 Filed Nov 17, 2023 17:37 UTC	HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133	PurchaseCommon Stock	150,000	$0.92	$137,970.00	Disclosure SEC source: 0001209191-23-055664 · doc4.xml · nonDerivative · entry 1 Collard Craig A · CIK 0001363558 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 186,496 F1 · price: The range of purchase prices paid was $0.8888 to $0.94. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information will be provided regarding the number of shares purchased at each separate price. Read SEC document
August 22, 2023 Filed Aug 24, 2023 20:09 UTC	HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133	Tax withholdingCommon Stock	692	$1.65	$1,141.80	Disclosure SEC source: 0001209191-23-047180 · doc4.xml · nonDerivative · entry 1 Collard Craig A · CIK 0001363558 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,496 F1 · acquired: Represents the withholding by the Company of certain of the vested shares of restricted stock to satisfy the minimum statutory tax obligations applicable to the quarterly vesting of shares from the restricted stock grant made on February 22, 2023. Read SEC document
June 22, 2023 Filed Jun 26, 2023 18:40 UTC	TerrAscend Corp. TRSSF · Entity 6184	GrantCommon Stock	132,647	$0.00	$0.00	Disclosure SEC source: 0001209191-23-039624 · doc4.xml · nonDerivative · entry 1 Collard Craig A · CIK 0001363558 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 553,513 F1 · shares: These shares represent an annual grant of restricted share units ("RSUs") for service as a director of the Issuer. The shares underlying the RSUs will vest in full on December 31, 2023, subject to the Reporting Person's continuous service with the Issuer as of the vesting date. Read SEC document
May 22, 2023 Filed May 24, 2023 21:04 UTC	HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133	Tax withholdingCommon Stock	691	$1.45	$1,001.95	Disclosure SEC source: 0001209191-23-031910 · doc4.xml · nonDerivative · entry 1 Collard Craig A · CIK 0001363558 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,188 F1 · acquired: Represents the withholding by the Company of certain of the vested shares of restricted stock to satisfy the minimum statutory tax obligations applicable to the quarterly vesting of shares from the restricted stock grant made on February 22, 2023. Read SEC document
April 03, 2023 Filed Apr 5, 2023 21:10 UTC	HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133	GrantEmployee Performance Stock Option (Right to Buy) · Derivative	4,250,000	$0.00 Strike: $1.78	$0.00	Disclosure SEC source: 0001209191-23-023385 · doc4.xml · derivative · entry 3 Collard Craig A · CIK 0001363558 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,250,000 Underlying: Common Stock · 4,250,000 shares Expires 2033-04-03 F3 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to escalating portions of the option grant upon the Issuer's stock price reaching certain pre-established levels ranging from $4.50 to $9.00 per share, subject to the Reporting Person's continued service to the Issuer through the vesting date. Read SEC document
April 03, 2023 Filed Apr 5, 2023 21:10 UTC	HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133	GrantRestricted Stock Units · Derivative	250,000	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001209191-23-023385 · doc4.xml · derivative · entry 2 Collard Craig A · CIK 0001363558 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires not disclosed F2 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning one year after the date of grant, subject to the Reporting Person's continued service to the Issuer through the vesting date. F2 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning one year after the date of grant, subject to the Reporting Person's continued service to the Issuer through the vesting date. Read SEC document
April 03, 2023 Filed Apr 5, 2023 21:10 UTC	HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133	GrantEmployee Stock Option (Right to Buy) · Derivative	3,000,000	$0.00 Strike: $1.78	$0.00	Disclosure SEC source: 0001209191-23-023385 · doc4.xml · derivative · entry 1 Collard Craig A · CIK 0001363558 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,000,000 Underlying: Common Stock · 3,000,000 shares Expires 2033-04-03 F1 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 750,000 shares on the first anniversary of the date of grant, followed by 2,250,000 shares vesting ratably each month over the subsequent three years, such that 3,000,000 options will be fully vested on the four-year anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer through the vesting date. Read SEC document
March 02, 2023 Filed Mar 3, 2023 14:25 UTC	OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992	Disposition to issuerStock Option (right to buy) · Derivative	2,500	$0.00 Strike: $13.30	$0.00	Disclosure SEC source: 0001385508-23-000075 · wf-form4_167785348993929.xml · derivative · entry 6 Collard Craig A · CIK 0001363558 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,500 shares Expires 2031-06-14 F3 · kind: The option was cancelled pursuant to the Merger Agreement, in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of disposed option shares. Read SEC document
March 02, 2023 Filed Mar 3, 2023 14:25 UTC	OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992	Disposition to issuerCommon Stock · Derivative	2,500	$0.00 Strike: $8.79	$0.00	Disclosure SEC source: 0001385508-23-000075 · wf-form4_167785348993929.xml · derivative · entry 5 Collard Craig A · CIK 0001363558 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,500 shares Expires 2030-06-15 F3 · kind: The option was cancelled pursuant to the Merger Agreement, in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of disposed option shares. Read SEC document
March 02, 2023 Filed Mar 3, 2023 14:25 UTC	OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992	Disposition to issuerStock Option (right to buy) · Derivative	2,500	$0.00 Strike: $12.75	$0.00	Disclosure SEC source: 0001385508-23-000075 · wf-form4_167785348993929.xml · derivative · entry 4 Collard Craig A · CIK 0001363558 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,500 shares Expires 2029-06-11 F3 · kind: The option was cancelled pursuant to the Merger Agreement, in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of disposed option shares. Read SEC document
March 02, 2023 Filed Mar 3, 2023 14:25 UTC	OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992	Disposition to issuerCommon Stock · Derivative	5,000	$0.00 Strike: $17.61	$0.00	Disclosure SEC source: 0001385508-23-000075 · wf-form4_167785348993929.xml · derivative · entry 3 Collard Craig A · CIK 0001363558 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2028-10-29 F3 · kind: The option was cancelled pursuant to the Merger Agreement, in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of disposed option shares. F3 · derivative.exercise_date: The option was cancelled pursuant to the Merger Agreement, in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of disposed option shares. Read SEC document
March 02, 2023 Filed Mar 3, 2023 14:25 UTC	OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992	Disposition to issuerCommon Stock	2,000	$20.00	$40,000.00	Disclosure SEC source: 0001385508-23-000075 · wf-form4_167785348993929.xml · nonDerivative · entry 2 Collard Craig A · CIK 0001363558 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · kind: Disposed of pursuant to the Merger Agreement in exchange for the Merger Consideration. The number of shares disposed of reflects 2,000 shares of Common Stock upon the acceleration of vesting of restricted stock units in accordance with the Merger Agreement. Read SEC document
March 02, 2023 Filed Mar 3, 2023 14:25 UTC	OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992	Disposition to issuerCommon Stock	53,822	$20.00	$1,076,440.00	Disclosure SEC source: 0001385508-23-000075 · wf-form4_167785348993929.xml · nonDerivative · entry 1 Collard Craig A · CIK 0001363558 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 F1 · kind: Disposed of pursuant to that certain Agreement and Plan of Merger between the Issuer, Indivior Inc., and Olive Acquisition Subsidiary, Inc., dated as of November 13, 2022 (the "Merger Agreement"), in exchange for a cash payment of $20.00 per share without interest thereon (the "Merger Consideration"). Read SEC document
September 23, 2022 Filed Sep 27, 2022 16:00 UTC	TerrAscend Corp. TRSSF · Entity 6184	PurchaseCommon Stock	60,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-22-103243 · tm2226644-2_4seq1.xml · nonDerivative · entry 1 Collard Craig A · CIK 0001363558 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 420,866 F1 · price: The weighted average purchase price for the transaction reported was $1.35, and the ranges of prices were between $1.34 and $1.36. Upon request from the SEC staff, the issuer or any security holder of the issuer, full information regarding the number of shares purchased at each separate price will be provided. Read SEC document
September 22, 2022 Filed Sep 26, 2022 16:26 UTC	TerrAscend Corp. TRSSF · Entity 6184	PurchaseCommon Stock	120,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-22-102917 · tm2226644-1_4seq1.xml · nonDerivative · entry 1 Collard Craig A · CIK 0001363558 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 360,866 F1 · price: The weighted average purchase price for the transaction reported was $1.51, and the ranges of prices were between $1.49 and $1.55. Upon request from the SEC staff, the issuer or any security holder of the issuer, full information regarding the number of shares purchased at each separate price will be provided. Read SEC document
July 01, 2022 Filed Jul 1, 2022 16:37 UTC	Sierra Oncology, Inc. SRRA · Entity 125698	Disposition to issuerStock Option (right to buy) · Derivative	6,000	$0.00 Strike: $18.11	$0.00	Disclosure SEC source: 0001209191-22-040255 · doc4.xml · derivative · entry 3 Collard Craig A · CIK 0001363558 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,000 shares Expires 2031-06-08 F2 · price: Pursuant to the terms of the merger agreement between issuer, GlaxoSmithKline plc ("GSK") and a subsidiary of GSK, this option was cancelled on the effective date of the merger in exchange for a cash payment equal to, on a per share basis, the offer price of $55.00 less the exercise price. F3 · derivative.exercise_date: The option fully vested on June 8, 2022. Read SEC document
July 01, 2022 Filed Jul 1, 2022 16:37 UTC	Sierra Oncology, Inc. SRRA · Entity 125698	Disposition to issuerStock Option (right to buy) · Derivative	10,000	$0.00 Strike: $13.88	$0.00	Disclosure SEC source: 0001209191-22-040255 · doc4.xml · derivative · entry 2 Collard Craig A · CIK 0001363558 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2030-05-28 F2 · price: Pursuant to the terms of the merger agreement between issuer, GlaxoSmithKline plc ("GSK") and a subsidiary of GSK, this option was cancelled on the effective date of the merger in exchange for a cash payment equal to, on a per share basis, the offer price of $55.00 less the exercise price. F1 · derivative.exercise_date: The option fully vested on May 28, 2021. Read SEC document
July 01, 2022 Filed Jul 1, 2022 16:37 UTC	Sierra Oncology, Inc. SRRA · Entity 125698	Disposition to issuerCommon Stock	13,500	$55.00	$742,500.00	Disclosure SEC source: 0001209191-22-040255 · doc4.xml · nonDerivative · entry 1 Collard Craig A · CIK 0001363558 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document
June 27, 2022 Filed Jun 30, 2022 01:08 UTC	TerrAscend Corp. TRSSF · Entity 6184	GrantCommon Stock	77,918	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-22-075927 · tm2220111-1_4seq1.xml · nonDerivative · entry 2 Collard Craig A · CIK 0001363558 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 240,866 F2 · price: Represents a grant of an equity award that will vest on December 31, 2022. Read SEC document
June 27, 2022 Filed Jun 30, 2022 01:08 UTC	TerrAscend Corp. TRSSF · Entity 6184	GrantCommon Stock	36,496	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-22-075927 · tm2220111-1_4seq1.xml · nonDerivative · entry 1 Collard Craig A · CIK 0001363558 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,948 F1 · price: Represents a grant of an equity award that vested on the same as the grant, June 27, 2022. Read SEC document
June 14, 2022 Filed Jun 14, 2022 21:00 UTC	OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992	GrantCommon Stock	2,000	$0.00	$0.00	Disclosure SEC source: 0001385508-22-000090 · wf-form4_165524040681105.xml · nonDerivative · entry 1 Collard Craig A · CIK 0001363558 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,822 F1 · kind: 2,000 shares are represented by restricted stock units ("RSUs"). Each RSU represents the Reporting Person's right to receive one share of Common Stock of Issuer, subject to the vesting schedule: 100% vest on the one year anniversary date or the date of the 2023 Annual Shareholder Meeting, whichever is earlier, subject to the Reporting Person continuing as a service provider through each such date. F1 · shares: 2,000 shares are represented by restricted stock units ("RSUs"). Each RSU represents the Reporting Person's right to receive one share of Common Stock of Issuer, subject to the vesting schedule: 100% vest on the one year anniversary date or the date of the 2023 Annual Shareholder Meeting, whichever is earlier, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document
June 13, 2022 Filed Jun 13, 2022 20:55 UTC	OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992	PurchaseCommon Stock	4,037	$10.94	$44,148.63	Disclosure SEC source: 0001385508-22-000076 · wf-form4_165515371990084.xml · nonDerivative · entry 2 Collard Craig A · CIK 0001363558 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,822 F2 · price: This transaction was executed in multiple trades at prices ranging from $10.82 to $10.95. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
June 10, 2022 Filed Jun 13, 2022 20:55 UTC	OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992	PurchaseCommon Stock	1,663	$11.50	$19,117.85	Disclosure SEC source: 0001385508-22-000076 · wf-form4_165515371990084.xml · nonDerivative · entry 1 Collard Craig A · CIK 0001363558 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,785 F1 · price: This transaction was executed in multiple trades at prices ranging from $11.48 to $11.50. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
May 16, 2022 Filed May 17, 2022 20:02 UTC	OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992	PurchaseCommon Stock	27,150	$13.54	$367,611.00	Disclosure SEC source: 0001385508-22-000061 · wf-form4_165281769689341.xml · nonDerivative · entry 1 Collard Craig A · CIK 0001363558 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,122 F1 · price: This transaction was executed in multiple trades at prices ranging from $12.10 to $13.99. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
May 13, 2022 Filed May 16, 2022 20:05 UTC	OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992	PurchaseCommon Stock	3,689	$10.49	$38,697.61	Disclosure SEC source: 0001385508-22-000058 · wf-form4_165273148149667.xml · nonDerivative · entry 1 Collard Craig A · CIK 0001363558 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,972 F1 · price: This transaction was executed in multiple trades at prices ranging from $10.47 to $10.50. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
January 06, 2022 Filed Jan 11, 2022 02:30 UTC	TerrAscend Corp. TRSSF · Entity 6184	OtherWarrants (right to buy) · Derivative	52,939	$0.00 Strike: $2.54	$0.00	Disclosure SEC source: 0001104659-22-002883 · tm2129883-13_4seq1.xml · derivative · entry 2 Collard Craig A · CIK 0001363558 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 52,939 shares Expires 2022-01-14 Read SEC document
January 06, 2022 Filed Jan 11, 2022 02:30 UTC	TerrAscend Corp. TRSSF · Entity 6184	OtherCommon Shares	52,939	$2.54	$134,465.06	Disclosure SEC source: 0001104659-22-002883 · tm2129883-13_4seq1.xml · nonDerivative · entry 1 Collard Craig A · CIK 0001363558 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,452 Read SEC document
November 24, 2021 Filed Nov 24, 2021 19:07 UTC	Sierra Oncology, Inc. SRRA · Entity 125698	PurchaseCommon Stock	7,899	$23.09	$182,348.42	Disclosure SEC source: 0001209191-21-066860 · doc4.xml · nonDerivative · entry 2 Collard Craig A · CIK 0001363558 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,500 F2 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares purchased. These shares were purchased in multiple transactions at prices ranging from $22.645 to $23.10, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the SEC staff, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. Read SEC document
November 23, 2021 Filed Nov 24, 2021 19:07 UTC	Sierra Oncology, Inc. SRRA · Entity 125698	PurchaseCommon Stock	5,601	$22.95	$128,514.95	Disclosure SEC source: 0001209191-21-066860 · doc4.xml · nonDerivative · entry 1 Collard Craig A · CIK 0001363558 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,601 F1 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares purchased. These shares were purchased in multiple transactions at prices ranging from $22.625 to $23.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the SEC staff, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. Read SEC document
September 13, 2021 Filed Sep 15, 2021 20:01 UTC	OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992	GrantCommon Stock	700	$18.07	$12,649.00	Disclosure SEC source: 0001385508-21-000131 · wf-form4_163173607782364.xml · nonDerivative · entry 3 Collard Craig A · CIK 0001363558 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,283 F3 · price: This transaction was executed in multiple trades at prices ranging from $18.02 to $18.15. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
September 13, 2021 Filed Sep 15, 2021 20:01 UTC	OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992	GrantCommon Stock	506	$17.96	$9,087.76	Disclosure SEC source: 0001385508-21-000131 · wf-form4_163173607782364.xml · nonDerivative · entry 2 Collard Craig A · CIK 0001363558 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,583 F2 · price: This transaction was executed in multiple trades at prices ranging from $17.94 to $17.97. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
September 13, 2021 Filed Sep 15, 2021 20:01 UTC	OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992	PurchaseCommon Stock	2,500	$18.13	$45,325.00	Disclosure SEC source: 0001385508-21-000131 · wf-form4_163173607782364.xml · nonDerivative · entry 1 Collard Craig A · CIK 0001363558 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,077 F1 · price: This transaction was executed in multiple trades at prices ranging from $18.05 to $18.16. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
September 10, 2021 Filed Sep 13, 2021 20:08 UTC	OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992	PurchaseCommon Stock	9,577	$18.18	$174,109.86	Disclosure SEC source: 0001385508-21-000126 · wf-form4_163156366596978.xml · nonDerivative · entry 1 Collard Craig A · CIK 0001363558 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,577 F1 · price: This transaction was executed in multiple trades at prices ranging from $18.06 to $18.20. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
June 15, 2021 Filed Jun 16, 2021 20:01 UTC	OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992	GrantStock Option (right to buy) · Derivative	2,500	$0.00 Strike: $13.30	$0.00	Disclosure SEC source: 0001385508-21-000083 · wf-form4_162387369433080.xml · derivative · entry 2 Collard Craig A · CIK 0001363558 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Stock · 2,500 shares Expires 2031-06-14 F2 · kind: On June 15, 2021, the reporting person was granted 2,500 non-qualified stock options. 100% of the options vest on the one year anniversary of the grant date or the date of the 2022 Annual Shareholder Meeting, whichever is earlier, subject to the Reporting Person continuing as a service provider through such date. Read SEC document
June 15, 2021 Filed Jun 16, 2021 20:01 UTC	OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992	GrantCommon Stock	2,000	$0.00	$0.00	Disclosure SEC source: 0001385508-21-000083 · wf-form4_162387369433080.xml · nonDerivative · entry 1 Collard Craig A · CIK 0001363558 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 F1 · kind: 2,000 shares are represented by restricted stock units ("RSUs"). Each RSU represents the Reporting Person's right to receive one share of Common Stock of Issuer, subject to the vesting schedule: 100% vest on the one year anniversary date or the date of the 2022 Annual Shareholder Meeting, whichever is earlier, subject to the Reporting Person continuing as a service provider through such date. Read SEC document
June 08, 2021 Filed Jun 9, 2021 10:50 UTC	Sierra Oncology, Inc. SRRA · Entity 125698	GrantStock Option (Right To Buy) · Derivative	6,000	$0.00 Strike: $18.11	$0.00	Disclosure SEC source: 0001209191-21-039094 · doc4.xml · derivative · entry 1 Collard Craig A · CIK 0001363558 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2031-06-08 F1 · derivative.exercise_date: The Option fully vests and becomes exercisable on June 8, 2022, subject to the Reporting Person's provision of service to the Issuer as of the vesting date. Read SEC document
June 15, 2020 Filed Jun 15, 2020 20:05 UTC	OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992	GrantCommon Stock · Derivative	2,500	$0.00 Strike: $8.79	$0.00	Disclosure SEC source: 0001385508-20-000071 · wf-form4_159225148826104.xml · derivative · entry 2 Collard Craig A · CIK 0001363558 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Stock · 2,500 shares Expires 2030-06-15 F2 · kind: On June 15, 2020, the Reporting Person was granted 2,500 non-qualified stock options. 100% of the options vest on the one year anniversary of the grant date or the date of the 2021 Annual Shareholder Meeting, whichever is earlier, subject to the Reporting Person continuing as a service provider through such date. F2 · derivative.exercise_date: On June 15, 2020, the Reporting Person was granted 2,500 non-qualified stock options. 100% of the options vest on the one year anniversary of the grant date or the date of the 2021 Annual Shareholder Meeting, whichever is earlier, subject to the Reporting Person continuing as a service provider through such date. Read SEC document
June 15, 2020 Filed Jun 15, 2020 20:05 UTC	OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992	GrantCommon Stock	2,000	$0.00	$0.00	Disclosure SEC source: 0001385508-20-000071 · wf-form4_159225148826104.xml · nonDerivative · entry 1 Collard Craig A · CIK 0001363558 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 F1 · kind: 2,000 shares are represented by restricted stock units ("RSUs"). Each RSU represents the Reporting Person's right to receive one share of Common Stock of Issuer, subject to the vesting schedule: 100% vest on the one year anniversary date or the date of the 2021 Annual Shareholder Meeting, whichever is earlier, subject to the Reporting Person continuing as a service provider through such date. Read SEC document
May 28, 2020 Filed May 29, 2020 16:32 UTC	Sierra Oncology, Inc. SRRA · Entity 125698	GrantStock Option (right to buy) · Derivative	10,000	$0.00 Strike: $13.88	$0.00	Disclosure SEC source: 0001209191-20-032947 · doc4.xml · derivative · entry 1 Collard Craig A · CIK 0001363558 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2030-05-28 F1 · derivative.exercise_date: The option vests as to 1/12 of the total shares monthly, beginning on June 28, 2020, with 100% of the total shares vested and exercisable on May 28, 2021, subject to the Reporting Person's provision of service to the issuer on each vesting date. Read SEC document
June 12, 2019 Filed Jun 13, 2019 20:07 UTC	OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992	GrantStock Option (right to buy) · Derivative	2,500	$0.00 Strike: $12.75	$0.00	Disclosure SEC source: 0001385508-19-000062 · wf-form4_156045640489628.xml · derivative · entry 1 Collard Craig A · CIK 0001363558 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Stock · 2,500 shares Expires 2029-06-11 F1 · derivative.exercise_date: On June 12, 2019, the reporting person was granted 2,500 non-qualified stock options. 100% of the options vest on the one year anniversary of the grant date. Read SEC document
October 29, 2018 Filed Oct 31, 2018 20:06 UTC	OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992	GrantCommon Stock · Derivative	5,000	$0.00 Strike: $17.61	$0.00	Disclosure SEC source: 0001385508-18-000098 · wf-form4_154101636286460.xml · derivative · entry 1 Collard Craig A · CIK 0001363558 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2028-10-29 F1 · derivative.exercise_date: On October 29, 2018, the reporting person was granted an option to purchase 5,000 shares of common stock. The options vest as follows: 33% of the options vest on the first, second and third anniversary of the grant date. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.